EX-FILING FEES 4 ex_717773.htm EXHIBIT FILING FEES ex_717773.htm

Exhibit 107

 

Calculation of Filing Fee Tables

 

Form S-1

(Form Type)

 

Windtree Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities and Carry Forward Securities

 

 

Security
Type

Security

Class

Title

Fee

Calculation

or Carry

Forward

Rule

Amount

Registered (1)

Proposed

Maximum

Offering

Price Per

Unit (2)

Maximum

Aggregate

Offering

Price

Fee

Rate

Amount of

Registration

Fee

Carry

Forward

Form

Type

Carry

Forward

File

Number

Carry

Forward

Initial

Effective

Date

Filing Fee

Previously

Paid In

Connection

with

Unsold

Securities

to be

Carried

Forward

Newly Registered Securities

Fees to Be

Paid

Equity

Common Stock, par value $0.001 per share

457(c)

10,679,758(3)

$10.64

$113,632,625.12

0.00014760

$16,772.18

        

Fees Previously Paid

—

—

 — — — —  

—

        

Carry Forward Securities

Carry Forward Securities

—

 — — —  

—

     — — — —
 

Total Offering Amounts

   $113,632,625.12   $16,772.18        
 

Total Fees Previously Paid

      

—

        
 

Total Fee Offsets

      

—

        
 

Net Fee Due

       $16,772.18        

 

(1)

Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover an indeterminate number of shares of common stock, par value $0.001 per share (“Common Stock”), of Windtree Therapeutics, Inc. (the “Registrant”) that may be issued and resold resulting from stock splits, stock dividends or similar transactions.

(2)

Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the shares of Common Stock on the Nasdaq Capital Market on August 22, 2024. This calculation is in accordance with Rule 457(c) of the Securities Act.

(3)

Includes (i) 10,574,018 shares of Common Stock that the Registrant may elect, in its sole discretion, to issue and sell to Seven Knots, LLC (“Seven Knots”) pursuant to a Common Stock Purchase Agreement, dated as of June 26, 2024, by and between the Registrant and Seven Knots (the “Purchase Agreement”) and (ii) 105,740 shares of Common Stock issuable upon the conversion of the outstanding unpaid principal balance, together with all accrued and unpaid interest, if any, of the convertible promissory note issued to Seven Knots as consideration for it entering into the Purchase Agreement.